SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta‑analysis.

H-D Wu et al.PubMed ↗Publisher ↗

What the trial testedas reported · 2021

Range includes no effect

No clear effect on adverse events & safety

−12%−40% to +28%

Bigger than 4 in 10 for adverse events & safety

As reported

HR 0.88, 95% CI 0.60–1.28

Not counted

Probably lowered adverse events & safety

−41%−61% to −9%

Bigger than 7 in 10 for adverse events & safety

As reported

HR 0.59, 95% CI 0.39–0.91

Two numbers in the abstract

the abstract, start to end

… in type 2 diabetes mellitus patients (HR 0.88, 95% CI 0.60-1.28, P > 0.05).

… with type 2 diabetes mellitus (HR 0.59, 95% CI 0.39-0.91, P = 0.02), …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

HR 0.880.60–1.28

Adverse events & safety

HR 0.590.39–0.91

MetforminAdverse events & safety

1 / 3

7 papers cite it

2021

2022

2023

2024

2025

2026

this paperpooled itcites it